We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aklief (trifarotene)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aklief (trifarotene)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Aklief (trifarotene) is a topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.

    Aklief is specifically indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

    Aklief is supplied as a cream for topical administration. Apply a thin layer of Aklief Cream to the affected areas once daily, in the evening, on clean and dry skin. 
     
    • One pump actuation should be enough to cover the face (i.e., forehead, cheeks, nose, and chin). 

    • Two actuations of the pump should be enough to cover the upper trunk (i.e., reachable upper back, shoulders and chest). One additional pump actuation may be used for middle and lower back if acne is present.

    The use of a moisturizer is recommended as frequently as needed from the initiation of treatment.  Avoid contact with the eyes, lips, paranasal creases, mucous membranes.

    Clinical Results

    FDA Approval

    The FDA approval was based on data from two pivotal Phase 3 clinical trials of once-daily Aklief Cream in patients with moderate acne on the face and trunk. The two identical 12-week, randomized, multicenter, parallel group, double-blind, vehicle-controlled clinical trials enrolled 2,420 patients. Results showed that Aklief Cream significantly reduced inflammatory lesions as early as two weeks on the face and four weeks on the back, shoulders and chest compared to vehicle. Aklief Cream was well tolerated when used on the face, back, shoulders and chest. 

    Side Effects

    Adverse effects associated with the use of Aklief cream may include, but are not limited to, the following:

    application site irritation

    application site pruritus

    sunburn

    Mechanism of Action

    Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.

    Additional Information

    For additional information regarding Aklief or acne vulgaris please visit the Aklief web page.

    Approval Date: 2019-10-01
    Date Created: 2019-10-08 08:29:09
    Company Name: Galderma
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing